相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Allogeneic transplantation for CML in the TKI era: striking the right balance
Andrew J. Innes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
Management of chronic myeloid leukemia in blast crisis
S. Saussele et al.
ANNALS OF HEMATOLOGY (2015)
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
Jianxiang Wang et al.
BLOOD (2015)
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
Simona Soverini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2015)
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
T. P. Hughes et al.
LEUKEMIA (2015)
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
F. Castagnetti et al.
LEUKEMIA (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
J. H. Lipton et al.
LEUKEMIA RESEARCH (2015)
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
Gabriele Gugliotta et al.
HAEMATOLOGICA (2015)
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T. Yeung et al.
BLOOD (2015)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Peter Valent et al.
BLOOD (2015)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
Tim H. Bruemmendorf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
D. Rea et al.
LEUKEMIA (2015)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Timothy P. Hughes et al.
BLOOD (2014)
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Hagop M. Kantarjian et al.
BLOOD (2014)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms
Dennis Niebel et al.
BLOOD (2014)
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Timothy P. Hughes et al.
BLOOD (2014)
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Neil P. Shah et al.
BLOOD (2014)
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Lucien Noens et al.
HAEMATOLOGICA (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology
Susan O'Brien et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24
Fabio Efficace et al.
QUALITY OF LIFE RESEARCH (2014)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus et al.
BLOOD (2013)
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
Loretta A. Williams et al.
BLOOD (2013)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
Antonella Russo Rossi et al.
HAEMATOLOGICA (2013)
Predictors of survival in thrombotic thrombocytopenic purpura
Shruti Chaturvedi et al.
HAEMATOLOGICA (2013)
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy
Sabina Chiaretti et al.
HAEMATOLOGICA (2013)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F. J. Giles et al.
LEUKEMIA (2013)
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
F. J. Giles et al.
LEUKEMIA (2013)
Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review
Fabio Efficace et al.
LEUKEMIA RESEARCH (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
David Montani et al.
CIRCULATION (2012)
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Gianantonio Rosti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Deborah L. White et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial
Andreas L. Petzer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Karl J. Aichberger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor
Jorge Cortes et al.
CANCER (2011)
Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000-a report from the population-based CAMELIA Registry
Edgar Faber et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Severe Peripheral Arterial Disease During Nilotinib Therapy
Philipp Le Coutre et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia
Sang Kyun Sohn et al.
LEUKEMIA & LYMPHOMA (2011)
Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease
Andreas Hochhaus
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
Optimizing Therapy for Patients With Chronic Myelogenous Leukemia in Chronic Phase
Hagop M. Kantarjian et al.
CANCER (2010)
Pleural effusions due to dasatinib
Anupama G. Brixey et al.
CURRENT OPINION IN PULMONARY MEDICINE (2010)
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
Francisco Cervantes et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
Neil P. Shah et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner
Teodora Pene-Dumitrescu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Fausto Castagnetti et al.
BLOOD (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Susan Branford et al.
BLOOD (2009)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Michele Baccarani et al.
BLOOD (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)
Hagop Kantarjian et al.
CANCER (2009)
High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes et al.
BLOOD (2008)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
Deborah White et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gianantonio Rosti et al.
NATURE MEDICINE (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
D White et al.
BLOOD (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center -: A 4.5-year follow-up
T Lahaye et al.
CANCER (2005)
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti et al.
BLOOD (2004)
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α
HM Kantarjian et al.
BLOOD (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
